Vaccine Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
- Transparency Market Research
A vaccine is a biological product which gives active acquired immunity to a particular disease.Vaccines have always been considered as a less profitable business described by high entrance hurdles. Stringent regulatory standards combined with significant fixed costs, and production & development related complications, have partial competition between vaccine producers. Moreover, these complications have restricted invention to a great extent. In the past, companies operating in the vaccines market were only focused on the development of preventive vaccines against contagious diseases.
Current developments in biomanufacturing and biotechnology have resulted in the growth of innovative technologies that are competent of addressing the problems related with the manufacture of vaccines. The beginning of therapeutic vaccines has paved way for vaccines to be manufactured for a range of degenerative and chronic diseases. This has resulted in the entry of several emerging and established investors in this field. In addition, the trend of subcontracting has developed significantly in the biopharmaceuticals manufacturing. Large and small business’ stakeholders are focusing on subcontracting their products due to the complexities involved in the manufacturing and development of vaccines. Factors such as decreased time to market, cost benefits in infrastructure, and operational benefits are the major factors driving the growth of the global vaccine contract manufacturing market.
The development of vaccines involves specified resources and supervised technology platforms, which are becoming progressively problematic to start in-house. Big pharmaceutical companies carry out most of these procedures in-house and are entering into long-term collaboration with reliable contract manufacturing organizations (CMOs). On the other hand, emerging and smaller players are subcontracting a comparatively larger share of their scientific and commercial development processes to contract manufacturing partners. CMOs are increasing their service ranges to deliver end-to-end facilities to sponsors and clients in order to strengthen their existence in the market. Advancements in technology, including the introduction of new expression systems such as GPEx and EB66 cell lines and cell culture media platforms, are major drivers of the market growth. Disposable/single-use technologies are becoming popular among contract manufacturers.
The global market for vaccine contract manufacturing is segmented into service type, vaccine type, product type, and region. Based on service type, the global market is segmented into fill/finish and bulk product. In terms of vaccine type, the market is divided into synthetic vaccines, toxoid vaccines, recombinant vector vaccines, inactivated vaccines, conjugate vaccines, live attenuated vaccines, and subunit vaccines. Based on product type, the market is categorized into single vaccines and combined vaccines. The single vaccines segment is further classified into tuberculosis, polio, tetanus, chickenpox, smallpox, influenza virus, Ebola virus, and others.
Geographically, the global vaccine contract manufacturing market is distributed over North America, Asia Pacific, Europe, and Rest of the World. North America dominates the global market due to the presence of a large number of contract manufacturing organizations. About 41 CMOs are present in different locations in the U.S. Europe is the second largest market for vaccine contract manufacturing with about 20 CMOs located in the U.K., France, and Germany. The market in Asia Pacific is expected to expand at a high growth rate during the forecast period owing to rapidly developing economies such as China and India.
Key market players operating in the global vaccine contract manufacturing market includes Minneapolis Medical Research Foundation (MMRF), Thomas Jefferson University, FUJIFILM Diosynth Biotechnologies, Emergent BioSolutions, BioMark, Goodwin Biotechnology, Inc., Bavarian Nordic A/S, Soligenix Inc., and Catalent Biologics.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Healthcare
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017